We are live on
!
Find out more
Deerfield Management Portfolio holdings
AUM
$9.59B
Turnover
24.47%
1-Year Est. Return
113.36%
This Fund
S&P 500
This Quarter
Est. Return
+6.55%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$8.48B
AUM Growth
+$646M
(+8.3%)
Cap. Flow
-$743M
Cap. Flow
% of AUM
-8.77%
Top 10 Holdings %
Top 10 Hldgs %
50.85%
Holding
160
New
9
Increased
14
Reduced
10
Closed
78
Avg Time Held Equity + Options
2
years
Top 10 Avg Time Held Equity + Options
1.1
years
Top 20 Avg Time Held Equity + Options
1.5
years
Avg Time Held Equity only
2
years
Top 10 Avg Time Held Equity only
1.1
years
Top 20 Avg Time Held Equity only
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Inspire Medical Systems
INSP
|
+$83.8M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$82.1M |
| 3 |
Pfizer
PFE
|
+$80.9M |
| 4 |
Genmab
GMAB
|
+$73.8M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$59.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$76.2M |
| 2 |
Revolution Medicines
RVMD
|
+$60.3M |
| 3 |
Phreesia
PHR
|
+$33.8M |
| 4 |
Ventas
VTR
|
+$27.4M |
| 5 |
Spyre Therapeutics
SYRE
|
+$23.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.65% |
| 2 | Miscellaneous | 15.35% |
| 3 | Consumer Discretionary | 0% |
| 4 | Consumer Staples | 0% |
| 5 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
Nuvalent
NUVL
| $1.77B | 20.85% |
17,248,450
| – | – |
2021 Q3
18 quarters
|
|
2
Cogent Biosciences
COGT
$4.88B
| $348M | 4.11% |
9,043,903
| – | – |
2020 Q4
21 quarters
|
|
3
Praxis Precision Medicines
PRAX
$6.67B
| $310M | 3.66% |
963,351
+60,000
| +7% | +$18.6M |
2025 Q1
4 quarters
|
|
4
Viatris
VTRS
$20B
| $273M | 3.22% |
20,206,170
| – | – |
2015 Q1
44 quarters
|
|
5
United Therapeutics
UTHR
$23.2B
| $271M | 3.2% |
457,000
+31,007
| +7% | +$15.4M |
2025 Q1
4 quarters
|
|
|
6
Revolution Medicines
RVMD
$41.5B
| $223M | 2.64% |
2,297,000
-597,613
| -21% | -$60.3M |
2020 Q1
24 quarters
|
|
7
Celcuity
CELC
$2.93B
| $196M | 2.31% |
1,714,000
| – | – |
2025 Q3
2 quarters
|
|
8
Centene
CNC
$34.7B
| $194M | 2.29% |
5,917,091
-530,907
| -8% | -$21.8M |
2018 Q1
32 quarters
|
|
9
Larimar Therapeutics
LRMR
$217M
| $160M | 1.89% |
35,606,974
+5,000,000
| +16% | +$20M |
2020 Q2
23 quarters
|
|
10
Brookdale Senior Living
BKD
$2.41B
| $159M | 1.88% |
11,637,032
| – | – |
2018 Q2
31 quarters
|
|
11
Vera Therapeutics
VERA
$1.93B
| $150M | 1.77% |
3,722,100
-337,595
| -8% | -$14.5M |
2025 Q1
4 quarters
|
|
12
Ionis Pharmaceuticals
IONS
$7.1B
| $149M | 1.75% |
1,979,669
| – | – |
2025 Q3
2 quarters
|
|
13
BioCryst Pharmaceuticals
BCRX
$2.06B
| $143M | 1.69% |
15,038,000
+697,000
| +5% | +$5.41M |
2023 Q1
12 quarters
|
|
|
14
Inspire Medical Systems
INSP
$1.97B
| $139M | 1.65% |
2,703,238
+1,197,366
| +80% | +$83.8M |
2025 Q2
3 quarters
|
|
15
Legend Biotech
LEGN
$3.7B
| $139M | 1.64% |
7,687,638
+1,755,638
| +30% | +$33.5M |
2024 Q4
5 quarters
|
|
16
AdaptHealth
AHCO
$834M
| $137M | 1.61% |
11,477,730
| – | – |
2019 Q4
25 quarters
|
|
17
NewAmsterdam Pharma
NAMS
$2.39B
| $137M | 1.61% |
4,264,789
+100,000
| +2% | +$3.26M |
2024 Q1
8 quarters
|
|
18
Acadia Healthcare
ACHC
$2.95B
| $106M | 1.25% |
4,520,000
| – | – |
2025 Q3
2 quarters
|
|
19
Arrowhead Research
ARWR
$8.25B
| $98.6M | 1.16% |
1,573,297
-259,649
| -14% | -$16.4M |
2025 Q3
2 quarters
|
|
20
DELISTED
Catalyst Pharmaceutical
CPRX
| $97.6M | 1.15% |
3,943,600
-967,561
| -20% | -$23.1M |
2022 Q3
14 quarters
|
|
21
Indivior Pharmaceuticals
INDV
$4.03B
| $94.4M | 1.11% |
3,097,790
-295,273
| -9% | -$9.75M |
2024 Q3
6 quarters
|
|
22
Xenon Pharmaceuticals
XENE
$3.28B
| $94M | 1.11% |
1,615,696
+1,073,676
| +198% | +$49.5M |
2025 Q2
3 quarters
|
|
23
Pharvaris
PHVS
$2.11B
| $88.3M | 1.04% |
3,126,042
| – | – |
2023 Q4
9 quarters
|
|
|
24
Syndax Pharmaceuticals
SNDX
$1.21B
| $88.3M | 1.04% |
+3,779,900
| New | +$82.1M |
2026 Q1
0 quarters
|
|
25
Tango Therapeutics
TNGX
$3.74B
| $86.8M | 1.02% |
4,146,813
+1,239,867
| +43% | +$17.3M |
2025 Q4
1 quarter
|
|
Similar funds
GGHC
Deerfield Management's Q1 2026 Portfolio in Review
As of Q1 2026, Deerfield Management held 160 positions worth $8.48B, up 8.3% from $7.83B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Deerfield Management withdrew a net $743M in Q1 2026, closing 78 positions and reducing 10 holdings. Its most notable exit was Phreesia, an estimated $33.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 87% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.
Against the trend, Deerfield Management opened a new position in Syndax Pharmaceuticals worth $88.3M.
- Deerfield Management's largest Q1 2026 buy was Syndax Pharmaceuticals: 3,779,900 shares worth $88.3M.
- Deerfield Management added most to Inspire Medical Systems in Q1 2026, an estimated $83.8M increase.
- Deerfield Management's biggest Q1 2026 reduction was Neurocrine Biosciences, cutting an estimated $76.2M.
- Deerfield Management fully exited Phreesia in Q1 2026, selling an estimated $33.8M.
- Deerfield Management's ten largest holdings make up 51% of its $8.48B portfolio in Q1 2026.
- Deerfield Management opened 9 new positions and closed 78 in Q1 2026.
- Deerfield Management's portfolio value rose 8.3% quarter-over-quarter to $8.48B.
Based on Deerfield Management's 13F filing for Q1 2026, filed 15 May 2026.